|name||focally amplified long non-coding RNA in epithelial cancer|
|alias_name||focally amplified lncRNA on chromosome 1|
|Cancer||ovarian cancer,thyroid cancer,|
LncRNA FAL1, its copy number and expression are correlated with outcomes in ovarian cancer. FAL1 associates with the epigenetic repressor BMI1 and regulates its stability in order to modulate the transcription of a number of genes including CDKN1A. The oncogenic activity of FAL1 is partially attributable to its repression of p21. FAL1-specific siRNAs significantly inhibit tumor growth (1).
Besides, FAL1 expression is increased in thyroid cancer (PTC) and high FAL1 expression increases the risk of multifocality (2).
|LncRNA||tissue||cancer type||expression level||oncogene/suppress gene||pathway||binding gene/factor||associated gene/factor||proliferation||apoptosis||migration||EMT||invasion||metastasis||prognosis||tag||PMID|
Expression profile in human body map
Expression profile in TCGA
. Hu X, Feng Y, Zhang D, Zhao SD, Hu Z, et al. (2014). A functional genomic approach identifies FAL1 as an oncogenic long noncoding RNA that associates with BMI1 and represses p21 expression in cancer. Cancer Cell 26(3): 344-57. link pubmed
. Jeong S, Lee J, Kim D, Seol MY, Lee WK, et al. (2016). Relationship of Focally Amplified Long Noncoding on Chromosome 1 (FAL1) lncRNA with E2F Transcription Factors in Thyroid Cancer. Medicine (Baltimore) 95(4): e2592. link pubmed